Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory diseases, has appointed Jérémie Mariau as CEO.   Mariau’s arrival as the head of Thabor Therapeutics will further bolster the senior management team. Thabor will then be able to launch a new funding round by the end of the year, which will allow the company to progress to the next key stages in its development, up to initiation of the first-in-human clinical trials.   ...